Articolul precedent |
Articolul urmator |
369 4 |
Ultima descărcare din IBN: 2023-07-04 18:13 |
SM ISO690:2012 AVRICENCO, Mariana, HOLBAN, Tiberiu. Dynamics of platelet count concentration in cirrhosis with hepatitis c virus after treatment with direct-acting antivirals. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 91. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | |||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | |||||
|
|||||
Pag. 91-91 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Background. Thrombocytopenia is a common complication in chronic hepatitis C virus infection. The degree of thrombocytopenia is correlated with hepatocellular lesions and liver fibrosis. Direct-acting anivirals have been shown to have a beneficial effect on thrombocytopenia in cirrhosis with hepatitis C virus. Objective of the study. . Evaluation of the effect of direct acting antivirals on platelet count in patients with cirrhosis with hepatitis C virus Material and Methods. The randomized retrospective study included 144 cirrhotic patients with hepatitis C virus, who received treatment with direct-acting antivirals. Patients were divided into 2 groups, depending on the regimen and duration of treatment. Clinical, paraclinical and virological parameters were evaluated Results. At the initiation of antiviral therapy, severe thrombocytopenia (25-69 x 10⁹/l) was present in 31 (21.5%) patients, moderate (70-120 x 10⁹/l) was present in 68 (47.2%) patients. At the end of antiviral therapy, 15 (10.4%) patients maintained severe thrombocytopenia (52-65 x 10⁹/l), moderate in 69 (47.9%) patients. The distribution of patients, according to the fibrosis stage assessed by Fibroscan, was: stage F3 in 12 (8.3%) patients, stage F4 – 132 (91.6%) patients. The biochemical response was obtained in both groups, the transaminase profile improving at the end of treatment. The sustained virological response was present in 135 (93.7%) patients. Conclusion. Treatment with direct-acting antivirals is effective and safe in liver cirrhosis with hepatitis C virus. Eradication of the infection by obtaining a sustained virological response is an effective strategy in remission of thrombocytopenia and liver fibrosis. |
|||||
Cuvinte-cheie thrombocytopenia, cirrhosis, sofosbuvir, daclatasvir, ledipasvir, trombocitopenia, ciroza, sofosbuvir, daclatasvir, ledipasvir |
|||||
|